Global Vasculitis Market Research and Forecast to reach $446.2 million by 2035

Global vasculitis market was valued at $293.2 million in 2025 and is projected to reach $446.2 million by 2035, growing at a CAGR of 4.4% during the forecast Period (2026-2035). The global vasculitis market is influenced by the prevalence of autoimmune and inflammatory disorders, which contribute to the incidence of vasculitis worldwide. Market analysis includes evaluation of available therapies as well as diagnostic approaches. Regional differences in healthcare infrastructure, patient awareness, and access to treatment affect market dynamics. Trends in early diagnosis and personalized treatment approaches are being monitored for their impact on adoption rates. These factors collectively shape the current market landscape and patient care strategies.

Browse the full report description of “Vasculitis Market Size, Share & Trends Analysis By Type (Large Vessels, Medium Vessels and Small Vessels), By Diagnosis Tests (Blood Test, Urine Test, Imaging Test and Other), By Therapeutic Class (Corticosteroids, Immunosuppressants and Biologics) and By End Users (Hospitals and Clinics, Diagnosis Center, Research Institutes and Other), Forecast Period (2026-2035)” Of https://www.omrglobal.com/industry-reports/vasculitis-market

Future projections for the vasculitis market consider demographic changes, including aging populations and increasing chronic disease prevalence, which may expand the patient base. Advancements in targeted therapies and diagnostic accuracy are expected to influence treatment patterns. Policy and reimbursement frameworks are likely to affect therapy availability across regions. Cost considerations and healthcare resource allocation will continue to play a role in market growth. Overall, the market is expected to evolve gradually, driven by clinical, regulatory, and economic factors.

Innovation Leaders Transforming the Global Vasculitis Market Research and Forecast

The key players in the global vasculitis market include Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline (GSK) plc, Novartis AG, and Pfizer Inc., among others. Companies are transforming the Global Vasculitis Market by advancing regulatory authorisations for targeted therapies and supporting evidence from pivotal clinical trials that address specific forms of vasculitis. Continued engagement with regulators and ongoing monitoring of safety and efficacy data are integral to how companies adjust their vasculitis strategies and adapt to evolving clinical and regulatory environments.

• In February?2025, AbbVie Inc. received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommending upadacitinib (RINVOQ) for the treatment of adults with giant cell arteritis, based on Phase?3 SELECT?GCA data demonstrating sustained remission and reduced disease flares. This CHMP opinion is a key step toward final European Commission approval for RINVOQ in GCA across EU member states.

• In October?2024, the Vasculitis Foundation launched a new support group specifically for young adults aged 18 to 30 living with vasculitis, a group of autoimmune conditions marked by inflammation of blood vessels. The purpose of this group is to help members form connections, exchange experiences, ask for advice, share concerns, celebrate personal milestones, and provide mutual encouragement. This effort is part of the foundation’s wider range of support initiatives, which also includes online groups for families, parents, teenagers, and those affected by eosinophilic granulomatosis with polyangiitis — the rarest form of ANCA?associated vasculitis.

 Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By component
  • By technology
  • By portability
  • By application
• Regions Covered-
  • North America
  • Asia-Pacific
  • Europe
  • Rest of the world
• Competitive Landscape - Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline (GSK) plc, Novartis AG, and Pfizer Inc., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Vasculitis Market Research and Forecast Report Segment

By component

• Hardware
• Software

By technology

• Semi & fully immersive
• Non-immersive

By portability

• Head-mounted displays (HMD)
• Gesture-tracking devices (GTD)
• Projectors & display walls (PDW)

By application

• Gaming & entertainment
• Healthcare
• Aerospace & defense
• Commercial
• Enterprise / training / simulation
• Others

Global Vasculitis Market Research and Forecast Report Segment by Region

North America

• United States
• Canada

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Countries
• Rest of Asia-Pacific

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/vasculitis-market